Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing OncLive®, Oncology Nursing News®, and Medical World News®. Gina joined the company in 2015 and has held various positions on OncLive and Oncology Nursing News. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: firstname.lastname@example.org
Zolbetuximab Plus mFOLFOX6 Extends Survival for Patients with CLDN18.2+ Advanced Gastric/GEJ AdenocarcinomaJanuary 22nd 2023
For patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, treatment with zolbetuximab/mFOLFOX6 yielded a progression-free survival (PFS) of 10.61 months whereas placebo/mFOLFOX6 resulted in a PFS of 8.67 months.
Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALLDecember 19th 2022
Blinatumomab plus consolidation chemotherapy demonstrated a survival advantage for patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
Regardless of Prior Local Treatment, Patients With mHSPC Achieve Improved Long-Term Survival With Enzalutamide Plus ADTMay 16th 2022
A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.
Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPCMay 2nd 2022
The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.
2-Year Follow-Up Showcases Sotorasib Benefit in KRAS G12C+ NSCLCApril 15th 2022
Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.
Trastuzumab Deruxtecan Significantly Improves OS in Select Gastric/GEJ CancerJanuary 22nd 2022
Patients with HER2-positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma experienced a 40% reduced risk of mortality with fam-trastuzumab deruxtecan-nxki, compared with patients who received standard therapy.
Four-Year Follow-Up Shows Neoadjuvant Carboplatin/Paclitaxel Combo Improves Event-Free Survival in TNBCSeptember 26th 2021
A 4-year follow-up of patients with treatment-naïve triple-negative breast cancer who received carboplatin plus neoadjuvant paclitaxel, followed by doxorubicin and cyclophosphamide, suggests that the regime induces superior pathological complete response and event-free survival.
Preliminary Results Show Novel Combo Appears Safe in High-Risk Non-Muscle-Invasive Bladder CancerJuly 17th 2021
Preliminary study results recently presented at the 2021 European Association of Urology Congress demonstrate that the safety profile of the combination of Bacillus Calmette-Guérin (BCG) and mitomycin is comparable to BCG alone.